The Thoracic and Cardiovascular Surgeon, Table of Contents Thorac Cardiovasc Surg 2024; 72(04): 286-287DOI: 10.1055/s-0044-1779344 Reply to Letter to the Editor Does Xenotransplantation Offer a Large Benefit for Human Patients?—A Reply Authors Author Affiliations Michael Schmoeckel 1 Department of Cardiac Surgery, LMU Klinikum Grosshadern, Munich, Germany Joachim Denner 2 Institute of Virology, Free University of Berlin, Germany Bruno Reichart 3 DFG-Transregio-Sonderforschungsbereich TR127 “Xenotransplantation,” Walter-Brendel-Institute for Experimental Medicine, LMU Munich, Germany Eckhard Wolf 4 Gene Centre and Centre for Innovative Medical Models (CiMM), LMU Munich, Germany Christian Hagl 1 Department of Cardiac Surgery, LMU Klinikum Grosshadern, Munich, Germany 5 DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.), Partner Site Munich, Germany Recommend Article Abstract Buy Article(opens in new window) All articles of this category(opens in new window) Full Text References References 1 Schmoeckel M, Längin M, Reichart B. et al. Current status of cardiac xenotransplantation. Thorac Cardiovasc Surg 2024; 72 (04) 273-284 2 Gotbaum R, Gauzens C, Bennett Jr D, Mohiuddin M, Montgomery R. Is xenotransplantation ready for prime time?—ITT episode 22. N Engl J Med Podcast 2023; 389: e49 3 Anwar IJ, Berman DM, DeLaura I. et al. The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates. Sci Transl Med 2023; 15 (711) eadf6376 4 Denner J. Xenotransplantation can be safe: a reply. Camb Q Healthc Ethics 2024; 33 (01) 148-149